Literature DB >> 23319595

The MLK-related kinase (MRK) is a novel RhoC effector that mediates lysophosphatidic acid (LPA)-stimulated tumor cell invasion.

Olga Korkina1, Zhiwan Dong, Allison Marullo, Gregg Warshaw, Marc Symons, Rosamaria Ruggieri.   

Abstract

The small GTPase RhoC is overexpressed in many invasive tumors and is essential for metastasis. Despite its high structural homology to RhoA, RhoC appears to perform functions that are different from those controlled by RhoA. The identity of the signaling components that are differentially regulated by these two GTPases is only beginning to emerge. Here, we show that the MAP3K protein MRK directly binds to the GTP-bound forms of both RhoA and RhoC in vitro. However, siRNA-mediated depletion of MRK in cells phenocopies depletion of RhoC, rather than that of RhoA. MRK depletion, like that of RhoC, inhibits LPA-stimulated cell invasion, while depletion of RhoA increases invasion. We also show that active MRK enhances LPA-stimulated invasion, further supporting a role for MRK in the regulation of invasion. Depletion of either RhoC or MRK causes sustained myosin light chain phosphorylation after LPA stimulation. In addition, activation of MRK causes a reduction in myosin light chain phosphorylation. In contrast, as expected, depletion of RhoA inhibits myosin light chain phosphorylation. We also present evidence that both RhoC and MRK are required for LPA-induced stimulation of the p38 and ERK MAP kinases. In conclusion, we have identified MRK as a novel RhoC effector that controls LPA-stimulated cell invasion at least in part by regulating myosin dynamics, ERK and p38.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319595      PMCID: PMC3581392          DOI: 10.1074/jbc.M112.414060

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

1.  Cell migration and invasion assays.

Authors:  Aline Valster; Nhan L Tran; Mitsutoshi Nakada; Michael E Berens; Amanda Y Chan; Marc Symons
Journal:  Methods       Date:  2005-10       Impact factor: 3.608

2.  The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration.

Authors:  D Bian; C Mahanivong; J Yu; S M Frisch; Z K Pan; R D Ye; S Huang
Journal:  Oncogene       Date:  2006-04-06       Impact factor: 9.867

3.  RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.

Authors:  Celina G Kleer; Kent A Griffith; Michael S Sabel; Gary Gallagher; Kenneth L van Golen; Zhi-Fen Wu; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2005-09       Impact factor: 4.872

4.  Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3.

Authors:  Yan Du; Barbara C Böck; Karen A Schachter; Mary Chao; Kathleen A Gallo
Journal:  J Biol Chem       Date:  2005-10-27       Impact factor: 5.157

5.  Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.

Authors:  J-Y Pillé; C Denoyelle; J Varet; J-R Bertrand; J Soria; P Opolon; H Lu; L-L Pritchard; J-P Vannier; C Malvy; C Soria; H Li
Journal:  Mol Ther       Date:  2005-02       Impact factor: 11.454

6.  Myosin phosphatase targeting subunit 1 affects cell migration by regulating myosin phosphorylation and actin assembly.

Authors:  Donglan Xia; James T Stull; Kristine E Kamm
Journal:  Exp Cell Res       Date:  2004-12-30       Impact factor: 3.905

7.  Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma.

Authors:  Kaylene J Simpson; Aisling S Dugan; Arthur M Mercurio
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

8.  RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis.

Authors:  Anne Hakem; Otto Sanchez-Sweatman; Annick You-Ten; Gordon Duncan; Andrew Wakeham; Rama Khokha; Tak W Mak
Journal:  Genes Dev       Date:  2005-08-17       Impact factor: 11.361

Review 9.  The emerging role of lysophosphatidic acid in cancer.

Authors:  Gordon B Mills; Wouter H Moolenaar
Journal:  Nat Rev Cancer       Date:  2003-08       Impact factor: 60.716

Review 10.  Rho GTPases: promising cellular targets for novel anticancer drugs.

Authors:  Gerhard Fritz; Bernd Kaina
Journal:  Curr Cancer Drug Targets       Date:  2006-02       Impact factor: 3.428

View more
  10 in total

1.  Proteomic profiling identified multiple short-lived members of the central proteome as the direct targets of the addicted oncogenes in cancer cells.

Authors:  Tonggang Qi; Wei Zhang; Yun Luan; Feng Kong; Dawei Xu; Guanghui Cheng; Yunshan Wang
Journal:  Mol Cell Proteomics       Date:  2013-10-08       Impact factor: 5.911

2.  Activation of the Classical Mitogen-Activated Protein Kinases Is Part of the Shiga Toxin-Induced Ribotoxic Stress Response and May Contribute to Shiga Toxin-Induced Inflammation.

Authors:  Dakshina M Jandhyala; Amrita Ahluwalia; Jennifer J Schimmel; Arlin B Rogers; John M Leong; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2015-10-19       Impact factor: 3.441

3.  The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.

Authors:  C Rey; B Faustin; I Mahouche; R Ruggieri; C Brulard; F Ichas; I Soubeyran; L Lartigue; F De Giorgi
Journal:  Oncogene       Date:  2015-11-02       Impact factor: 9.867

4.  Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.

Authors:  E Semprucci; P Tocci; R Cianfrocca; R Sestito; V Caprara; M Veglione; V Di Castro; F Spadaro; G Ferrandina; A Bagnato; L Rosanò
Journal:  Oncogene       Date:  2015-11-02       Impact factor: 9.867

5.  The RhoGEF TEM4 Regulates Endothelial Cell Migration by Suppressing Actomyosin Contractility.

Authors:  Natalia Mitin; Kent L Rossman; Rachel Currin; Sandeep Anne; Thomas W Marshall; James E Bear; Victoria L Bautch; Channing J Der
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

6.  RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6.

Authors:  Charlotte H Durkin; Flavia Leite; João V Cordeiro; Yutaka Handa; Yoshiki Arakawa; Ferran Valderrama; Michael Way
Journal:  Dev Cell       Date:  2017-05-08       Impact factor: 12.270

7.  A Novel Zak Knockout Mouse with a Defective Ribotoxic Stress Response.

Authors:  Dakshina M Jandhyala; John Wong; Nicholas J Mantis; Bruce E Magun; John M Leong; Cheleste M Thorpe
Journal:  Toxins (Basel)       Date:  2016-09-02       Impact factor: 4.546

Review 8.  KAI1/CD82 gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers.

Authors:  Shuo Wang; Jiang Chen; Xiao-Zhong Guo
Journal:  World J Gastrointest Oncol       Date:  2022-08-15

9.  A RhoC biosensor reveals differences in the activation kinetics of RhoA and RhoC in migrating cells.

Authors:  Jon S Zawistowski; Mohsen Sabouri-Ghomi; Gaudenz Danuser; Klaus M Hahn; Louis Hodgson
Journal:  PLoS One       Date:  2013-11-05       Impact factor: 3.240

10.  Mixed lineage kinase ZAK promotes epithelial-mesenchymal transition in cancer progression.

Authors:  Linna Li; Ning Su; Ting Zhou; Dayong Zheng; Zheng Wang; Haoyu Chen; Shoujun Yuan; Wenliang Li
Journal:  Cell Death Dis       Date:  2018-02-02       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.